NCT01373333No Longer Available不适用
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
Compassionate use of orphan drug 3,4-Diaminopyridine(DAP) in Treatment of Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP is used to decrease the muscle weakness associated with LEMS and hopefully will decrease the need for prednisone and all other therapies that were previously required to control symptoms. How long a patient will take 3,4 DAP depends upon if he/she is seeing benefits from the medication or experiencing side effects that will prevent them from continuation in the study.
详细描述
3,4-diaminopyridine (3,4-DAP) decreases symptoms of weakness in patients with LEMS, and therefore can be used to decrease the amount of immune modulation therapy needed to provide an equivalent degree of disease control.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of LEMS with or without any of the following: evidence of underlying malignancy, presence of P/Q or N-type calcium channel antibodies, electrodiagnostic evidence of a presynaptic defect of neuromuscular junction transmission.None of these laboratory findings are required for inclusion in this study.
- •P/Q and N type calcium channel antibodies are measured in the blood as a routine laboratory test during the course of initial diagnosis, but 10-20% of patients with LEMS do not have elevated levels of these antibodies.
排除标准
- •Hypersensitivity to any component of this medication.
- •History of past or current seizures.
- •History of asthma.
- •Evidence of prolonged QT syndrome. There is no absolute upper limit of normal for the QTc interval.
- •Family history of prolonged QTc syndrome, history of unexplained syncope, seizures or cardiac arrest.
研究者
研究点 (1)
Loading locations...
相似试验
No Longer Available
不适用
Treatment of Lambert-Eaton Syndrome With 3,4 DiaminopyridineLambert-Eaton Myasthenic SyndromeNCT00994916David Lacomis, MD
Approved For Marketing
不适用
Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton SyndromeLambert Eaton Myasthenic SyndromeNCT01825395University of Colorado, Denver
No Longer Available
不适用
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)Lambert-Eaton Myasthenic Syndrome (LEMS)Congenital Myasthenia (CM)NCT02012933Oregon Health and Science University
No Longer Available
不适用
Treatment of Lambert-Eaton Syndrome With 3,4 DAPLambert Eaton Myasthenic SyndromeNCT00704925David P. Richman, MD
已完成
2 期
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic SyndromeLambert-Eaton Myasthenic SyndromeEaton-Lambert Myasthenic SyndromeNCT01511978Jacobus Pharmaceutical32